On 14 July 2023,Gland Pharma informed that the United States Food and Drug Administration (USFDA) had conducted good manufacturing practice (GMP) inspection at the company's Dundigal Facility at Hyderabad between 3 July 2023 and 14 July 2023. The inspection was concluded with one observation.

Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business to business (B2B) model. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India.

The company's consolidated net profit declined 15.3% to Rs 194.10 crore despite of 41.1% jump in revenue to Rs 1,208.69 crore in Q1 FY24 over Q1 FY23.

Shares of Gland Pharma rose 0.64% to Rs 1,591.40 on the BSE.